BioWin is proud to introduce you to its new cross-member: HalioDx.

This French company is at the forefront of Immuno-oncology diagnostics with a range of tools and a rich pipeline of proprietary immuno-oncology diagnostic applications such as Immunoscore®.

Together, we invite to our BioWinConnect "Delivering innovative biomarker assays for Immuno-oncology translational research & clinical trials"

One of the biggest challenge in cancer patient treatment today is to find accurately which patients will benefit from immunotherapy or combination of therapies.
For drug developers, the assessment of immune biomarkers through translational and clinical research studies allow a strong understanding of the tumor micro-environment and support the development of the biomarker strategy.
During this seminar, you will learn how HalioDx, thanks to its solid expertise in immuno-oncology diagnostic integrating innovative technologies can help biotech and pharma companies to access a multi-parameter approach based on the analysis and the understanding of the immune contexture of tumors.
We will present our IMMUNOGRAM platform (and its application to Colon Cancer) and the ATLAS program, allowing to get a personalized and dynamic “fingerprint” of tumor-immune system interaction that can be customized and adapted to the biologic question addressed by the drug developers.



-    9:00 Registration & coffee 
-    9:30 Welcome by
     Sandy Mercurio-Smit, PhD, Manager Business Development, HalioDx
              - Brightplex®, a powerful multiplexing technology to assess complex immune phenotypes in the tumor microenvironment 
              - IMMUNOGRAM, a comprehensive platform dedicated to Pharma Clinical Research programs 
     Jacques Fieschi, PhD, Senior Director R&D, HalioDx
-    Q&A session 
-    Networking 
-    12:00 End


Point Centre
Avenue Georges Lemaître 19B
6041 Gosselies (Belgique)

If you need to cancel your participation, please notify BioWin ([email protected]) at least 48 hours in advance. Without prior cancellation, the amount of € 50 per participant will be charged to the company to cover the costs. Thank you for your understanding.